Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04093505
Title Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG)
Acronym GnG
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors University Hospital Heidelberg
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.